Medytox has filed an appeal with the U.S. International Trade Commission (ITC), which ruled in favor of HUGEL in a lawsuit related to botulinum toxin.
On the 7th, HUGEL noted in a public announcement that "Medytox filed an appeal against the ITC last month with the U.S. Court of Appeals for the Federal Circuit (CAFC)." They added, "We will participate in the appeal as an interested party."
Earlier, Medytox claimed that HUGEL tried to export botulinum toxin to the U.S. by misappropriating its strain and manufacturing process and filed a complaint against HUGEL, HUGEL America, and its partner, Chromapharma, with the ITC in May 2022. Botulinum toxin is a medication derived from the bacteria that cause food poisoning, which causes muscle paralysis and helps to smooth wrinkles.
However, the ITC ruled in June of last year, following a preliminary ruling, and in October with a final ruling that "there is no support for the claims of strain misappropriation raised by Medytox," stating, "HUGEL did not violate the law, including tariff laws." In response, Medytox confirmed that "it is correct that we have appealed, and we will participate sincerely in the forthcoming procedures."